Nuvation Bio CRO receives 748,130-share option grant

Nuvation Bio Inc. reported that Chief Regulatory Officer Kerry Wentworth received a grant of stock options covering 748,130 shares of common stock on February 27, 2026.

Rhea-AI Filing Summary

Nuvation Bio Inc. reported that Chief Regulatory Officer Kerry Wentworth received a grant of stock options covering 748,130 shares of common stock on February 27, 2026. The option has an exercise price of $0.00 per share and vests 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to continued service. Following this grant, Wentworth also holds 53,000 shares of Class A common stock, including 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.

Insider Trade Summary

Grant/Award: 748,130 shares

Grant/Award 2 txns

Insider Wentworth Kerry

Role CHIEF REGULATORY OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	748,130	$0.00	$0.00
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 748,130 contracts (Direct); Class A Common Stock — 53,000 shares (Direct)

Footnotes (2)

1. F1. Includes 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.
2. F2. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuvation Bio (NUVB) report for Kerry Wentworth?

Nuvation Bio reported a stock option grant to Chief Regulatory Officer Kerry Wentworth. The award covers 748,130 shares at an exercise price of $0.00 per share, granted on February 27, 2026, as part of equity-based compensation.

How many stock options did Nuvation Bio (NUVB) grant to Kerry Wentworth?

Kerry Wentworth received stock options for 748,130 shares of Nuvation Bio common stock. These options represent a significant equity incentive and are structured to vest over time, aligning compensation with continued service at the company.

What is the vesting schedule for Kerry Wentworth’s Nuvation Bio (NUVB) stock options?

The options vest 25% on the one-year anniversary of February 27, 2026, then monthly over the next 36 months. Vesting is conditioned on Wentworth’s continuous service with Nuvation Bio on each applicable vesting date.

What is the exercise price of Kerry Wentworth’s Nuvation Bio (NUVB) stock options?

The reported exercise price for the stock option grant is $0.00 per share. This indicates the award functions as a compensatory grant, providing potential value as long as the underlying shares retain value over time.

How many Nuvation Bio (NUVB) common shares does Kerry Wentworth hold after this filing?

After the reported transactions, Kerry Wentworth holds 53,000 shares of Class A common stock directly. This includes 3,000 shares acquired on November 19, 2025 under Nuvation Bio’s 2021 Employee Stock Purchase Plan.

What plan was used for Kerry Wentworth’s prior Nuvation Bio (NUVB) share purchase?

A portion of Kerry Wentworth’s holdings—3,000 shares of Class A common stock—was acquired on November 19, 2025 under Nuvation Bio’s 2021 Employee Stock Purchase Plan, a program allowing employees to purchase company stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wentworth Kerry

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF REGULATORY OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock								53,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		748,130		(2)	02/26/2036	Class A Common Stock	748,130	$0	748,130	D

Explanation of Responses:

1. Includes 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.

2. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.